{"entity":{"id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of Trifluridine/tipiracil in colorectal cancer, run by Jiangsu Simcere Pharmaceutical Co., Ltd., now recruiting.","summary":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07361003 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 464 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-01. Interventions recorded: Suvemcitug injection, trifluridine/tipiracil tablets, Suvemcitug placebo injection, trifluridine/tipiracil tablets. Conditions listed: Refractory Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07361003","url":"https://clinicaltrials.gov/study/NCT07361003"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["trifluridine-tipiracil"],"companies":["simcere"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07361003","phase":"3","setting":"A Phase Ib/III Study of Suvemcitug Plus Trifluridine/Tipiracil Tablets (FTD/TPI) Versus Placebo Plus Trifluridine/Tipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","enrolled":464,"outcomes":[]},"route":"/trials/nct07361003/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"company":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"}]}}